| SEQ_NO | 1 | Date of announcement | 2026/06/29 | Time of announcement | 14:20:58 |
|---|---|---|---|---|---|
| Subject | Medigen Enrolls First Patient in Phase I/II Clinical Trial of Allogeneic NK Cell Therapy (Magicell-NK) | | | | |
| Date of events | 2026/06/29 | To which item it meets | paragraph 10 | | |

Statement

1.Date of occurrence of the event:2026/06/29
2.New drug name or code:Allogeneic natural killer cells (Magicell-NK)
3.Indication:Using allogeneic natural killer cell (Magicell-NK) as an adjuvant therapy for post-surgery combined with chemotherapy for patients with pancreatic ductal adenocarcitnoma (PDA) or cholangiocarcinoma, with the goal of preventing disease recurrence and prolonging survival.
4.Planned development stages:Phase I/II clinical trial.
5.Current development stage:
(1)Application submission/approval/disapproval/each of clinical trials(include interim analysis):
The Company's independently developed allogeneic natural killer (NK) cell therapy, Magicell-NK, has successfully enrolled its first patient (First Patient In) today (June 29, 2026) in a Phase I/II clinical trial evaluating Magicell-NK in combination with chemotherapy as an adjuvant treatment following surgical resection in patients with pancreatic ductal adenocarcinoma (PDAC) or cholangiocarcinoma. The trial is being conducted at National Cheng Kung University Hospital.
This Phase I/II study is expected to enroll up to 42 patients. The objective of the trial is to evaluate the use of the Company's allogeneic NK cell therapy, Magicell-NK, in combination with chemotherapy as a postoperative adjuvant treatment for patients with PDAC or cholangiocarcinoma, with the goal of preventing disease recurrence and improving patient survival outcomes.
(2)Once disapproved by competent authority or each of clinical trials (include interim analysis) results less than statistically significant sense, the risks & the associated measures the Company may occur: Not applicable.
(3)After obtaining official approval or the results of statistically significant sense, the future strategy: Not applicable.
(4)Accumulated investment expenditure incurred: Due to considerations of commercial strategy, disclosure is temporarily withheld.
6.Upcoming development plan:
(1)Estimated date of completion: Expected to be completed in 2029, the actual schedule will be adjusted according to the progress of execution.
(2)Estimated responsibilities: Our company will bear the expenses related to clinical trials and registration fees.
7.Market situation:
According to the latest global cancer statistics from the World Health Organization (WHO) in 2022, there were approximately 20 million new cancer cases and around 9.7 million cancer-related deaths worldwide in 2022, highlighting a worsening global cancer burden. In Taiwan, the Ministry of Health and Welfare reported that malignant tumors remained the leading cause of death in 2024 and pancreatic cancer ranks as the seventh leading cause of cancer-related mortality. Due to their high postoperative recurrence rates and the limited efficacy of adjuvant chemotherapy, pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma are considered highly aggressive malignancies and significant unmet medical needs persist in the treatment. According to a 2023 study, the overall recurrence rate of PDAC within five years after surgical resection is approximately 60–80%, with 25–38% of patients experiencing recurrence within the first six months following surgery. If the efficacy of allogeneic Magicell-NK is validated, it may offer a novel postoperative adjuvant treatment option for patients with PDAC or cholangiocarcinoma, helping to address these unmet medical needs.
8.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 8 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):none
9.New drug development requires long process, vast investments and with no guarantee in success which may pose investment risks.The investors are advised to exercise caution and conduct thorough evaluation.: